Infinity Pharmaceuticals to Present Corporate Overview at 38th Annual J.P. Morgan Global Healthcare Conference

Infinity Pharmaceuticals, Inc. INFI announced today that Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals, will provide a corporate overview at the 38^th Annual J.P. Morgan Global Healthcare Conference on Thursday, January 16, 2020 at 9:00 am Pacific Time at the Westin St. Francis Hotel in San Francisco, California.

A live webcast of the presentation will be available on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event.

About Infinity and IPI-549

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-1 is an ongoing Phase 1/1b study evaluating IPI-549 as a monotherapy and in combination with Opdivo (nivolumab) in approximately 225 patients with advanced solid tumors including patients refractory to anti-PD-1 therapy. MARIO-275 and MARIO-3 have recently initiated. MARIO-275 is a global, randomized, combination study of IPI-549 combined with Opdivo in I/O naïve urothelial cancer patients. MARIO-3 is the first IPI-549 combination study in front-line advanced cancer patients and is evaluating IPI-549 in combination with Tecentriq and Abraxane in front-line TNBC and in combination with Tecentriq and Avastin in front-line RCC. With the MARIO-275, MARIO-3 and the MARIO-1 studies, Infinity is evaluating IPI-549 in the anti-PD-1 refractory, I/O-naïve and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005204/en/